Study wrapper · #1268
Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.
Editor's note
A minireview with a stated but not fully systematic search, so the 16.1 percent BMI figure should be read as drawn from the adolescent semaglutide trial programme rather than independently pooled here. The honest part is the gap it names: adolescent evidence for tirzepatide and for the cagrilintide-semaglutide combination is close to absent, and long-term safety data in a growing population do not yet exist. The equity and cost discussion is the practical constraint clinicians will recognise. Adolescent dosing is a prescriber decision, not a reported-protocol question.
Plain-language abstract
An evidence review of medication options for adolescent obesity, restricted to randomised trials and meta-analyses in 12- to 18-year-olds running longer than 12 weeks. Semaglutide came out as the best-evidenced option, reported to lower BMI by about 16 percent and to improve insulin sensitivity more than liraglutide. Data on tirzepatide and CagriSema in this age group are still very limited, and cost and access inequity are recurring obstacles.